BioSpace News Archive

Oncorena announced the initiation of the Phase I-II clinical trial of the first-in-class compound orellanine in patients with advanced kidney cancer on dialysis.

Alligator Bioscience Alligator Bioscience, announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer.

XPhyto Therapeutics Corp. is pleased to announce the execution of Covid-ID Lab sales contracts with both digital life are Corona Testzentren, powered by digitallifecare GmbH, Germany and a group of pharmacies in Bamberg, Germany.

Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA therapeutics, announced that it has raised $26.3 Million in a Series B financing round led by Laureus Capital.

Sosei Group Corporation, announces that its Board of Directors approved the nomination of candidates for its Representative Executive Officer, Directors and Executive Officers as stated below.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next General Meeting.

Centogene N.V. announced the closing of a EUR 15 million private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures, as well as the entry into a USD 45 million senior secured loan facility provided by Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare companies.

Englewood Health has been recognized by the American College of Cardiology with the Transcatheter Valve Certification.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an investor conference in February 2022.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provides an update on the Phase III clinical trial, FLAMINGO-01.